Anhco Nguyen
Chief Tech/Sci/R&D Officer bei ATARA BIOTHERAPEUTICS, INC.
Vermögen: 653 330 $ am 31.03.2024
Profil
Anhco Nguyen's current job is as the Executive VP, Chief Scientific & Technical Officer at Atara Biotherapeutics, Inc. Dr. Nguyen's former jobs include being the Vice President-Research & Development at Enumeral Biomedical Holdings, Inc. from 2014 to 2016, an Associate at the Center for Cancer Research at Massachusetts Institute of Technology, and a Vice President at Fate Therapeutics, Inc. Dr. Nguyen's education includes a doctorate from the University of Washington and an undergraduate degree from Harvard College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 04.03.2024 | 941 397 ( 0,73% ) | 653 330 $ | 31.03.2024 |
Aktive Positionen von Anhco Nguyen
| Unternehmen | Position | Beginn |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 10.05.2021 |
Ehemalige bekannte Positionen von Anhco Nguyen
| Unternehmen | Position | Ende |
|---|---|---|
| ENUMERAL BIOMEDICAL HOLDINGS INC | Chief Tech/Sci/R&D Officer | 17.08.2016 |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Ausbildung von Anhco Nguyen
| University of Washington | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| FATE THERAPEUTICS, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Enumeral Biomedical Holdings, Inc.
 Enumeral Biomedical Holdings, Inc. BiotechnologyHealth Technology Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the business of discovering and developing novel antibody immunotherapies for the treatment of cancer and other diseases. It also focuses on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors. The company was founded by Barry C. Buckland, John J. Rydzewski, and Arthur H. Tinkelenberg on December 11, 2009 and is headquartered in Arlington, MA. | Health Technology |
